论文信息 - Metformin and reduced risk of cancer in diabetic patients

Metformin and reduced risk of cancer in diabetic patients

Metformin, widely given to patients with type 2 diabetes, works by targeting the enzyme AMPK (AMP activated protein kinase), which induces muscles to take up glucose from the blood. A recent breakthrough has found the upstream regulator of AMPK to be a protein kinase known as LKB1.1 2 LKB1 is a well recognised tumour suppressor. Activation of AMPK by metformin and exercise requires LKB1, and this would also explain why exercise is beneficial in the primary and secondary prevention of certain cancers.3 We hypothesise that metformin use in patients with type 2 diabetes may reduce their risk of cancer. We tested this hypothesis using record linkage databases developed in Tayside, Scotland: a diabetes clinical information system (DARTS) and a database of dispensed prescriptions (MEMO).4 We did a pilot case-control study using previously validated methods.5 From 314 127 people who were resident (or died) in Tayside in …

[1] T. Mäkelä,et al. LKB 1 is a master kinase that activates 13 protein kinases of the AMPK subfamily , including the MARK / PAR-1 kinases , 2004 .

[2] A. Bauman,et al. Updating the evidence that physical activity is good for health: an epidemiological review 2000-2003. , 2004, Journal of science and medicine in sport.

[3] D. P. Doogan. TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS , 1989, The Lancet.

[4] Jérôme Boudeau,et al. Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade , 2003, Journal of biology.

[5] D. Boyle,et al. The diabetes audit and research in Tayside Scotland (darts) study: electronic record linkage to create a diabetes register , 1997, BMJ.